Dr. Elyssa L. Barron, M.D.
Psychiatry (Psychiatry Physician)
At a glance
- In the NPI registry since
- 2011
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
NY license 271984
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 208 | 70 |
| Established patient office or other outpatient visit, 20-29 minutes | 41 | 29 |
| Assessment of emotional or behavioral problems | 21 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Buspirone Hcl Other prescribers in White Plains, NY | 20 |
| Olanzapine Other prescribers in White Plains, NY | 16 |
| Quetiapine Fumarate Other prescribers in White Plains, NY | 15 |
| Fluoxetine Hcl Other prescribers in White Plains, NY | 14 |
| Aripiprazole Other prescribers in White Plains, NY | 11 |
| Divalproex Sodium Er (divalproex sodium) Other prescribers in White Plains, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $15.40 in total to this clinician.
| Boston Scientific Corporation | $15.40 |
|---|
| Food and Beverage | $15.40 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 27 industry-funded studies in 2025, from 7 companies. The companies reported $11,224,714 in research payments for these studies, mostly to the institutions running them.
- Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia
E.r. Squibb & Sons, L.l.c. · Completed · NCT06572449 - Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) · Completed · NCT06627413 - ITI-007-452
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
E.r. Squibb & Sons, L.l.c. · Completed · NCT04820309 - A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
AbbVie Inc. · Completed · NCT05227703 - A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms
Axsome Therapeutics, Inc. - A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
E.r. Squibb & Sons, L.l.c. - A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)
E.r. Squibb & Sons, L.l.c. - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.